Clinical Trials Logo

Stroke, Ischemic clinical trials

View clinical trials related to Stroke, Ischemic.

Filter by:

NCT ID: NCT03394950 Active, not recruiting - Stroke, Ischemic Clinical Trials

Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke

Start date: December 30, 2017
Phase: Phase 4
Study type: Interventional

Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of morbidity, mortality and disability. A large number of studies have confirmed that the thrombolytic therapy can effectively open blood vessels and improve the functional prognosis of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients receiving thrombolysis will have good prognosis, while a large number of patients will still be disabled and even dead. How to improve the neurofunctional prognosis of thrombolytic patients has been a hot topic in the world. Butyl phthalide is type I chemical drugs. Some multicenter randomized, double-blind, placebo-controlled clinical trials have showed that acute ischemic stroke patients taking butyl phthalide has better lateral branch circulation and living ability score than patients taking placebo. Besides, butyl phthalide treatment is safe. The animal experiment indicated that buphthalein could significantly improve secondary side branch circulation, recover the microarterial diameter of the soft meninges in the ischemic region and increase the blood flow rate. Based on the discussion, we assume that: giving butyl phthalide to patients with acute ischemic stroke in advance, might promote and improve the formation of collateral circulation to freeze ischemia penumbra. Based on this hypothesis, we would like to explore the efficacy and safety of butyl phthalide combined with rtPA thrombolysis in the treatment of acute ischemic stroke.

NCT ID: NCT03360656 Not yet recruiting - Fever Clinical Trials

Transnasal Induction of Normothermia in Febrile Stroke Patients

Start date: December 2017
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate safety and performance of the COOLSTAT® Transnasal Thermal Regulating Device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.

NCT ID: NCT03355742 Not yet recruiting - Clinical trials for Coronary Artery Disease

XIENCE 28 Global Study

Start date: December 27, 2017
Phase: N/A
Study type: Interventional

XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family (XIENCE Xpedition Everolimus Eluting Coronary Stent System [EECSS], XIENCE Alpine EECSS, XIENCE PROX EECSS, or XIENCE Sierra EECSS of coronary drug-eluting stents

NCT ID: NCT03344146 Not yet recruiting - Stroke, Ischemic Clinical Trials

Electronic Monitoring and Improvement of Adherence to DOACs in Polymedicated Stroke Patients

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

Primary objective of the MAAESTRO trial is to evaluate the impact of an educational and reminder-based intervention on the adherence of stroke patients to DOACs. Secondary objectives are to evaluate the association between non-adherence and clinical events, to identify predictors of non-adherence and to compare objective measures of adherence with self-reporting. Key methodological instrument for this study will be the "Time4Med" pillbox with Smart/ Reminder Card. The study includes 3 visits (baseline visit 0, follow-up visit 1 and end-of-study visit 2) with a total follow-up of 12 months. After an initial 6-month observational phase with electronic monitoring of adherence using the "Smart Card", all patients will receive counselling based on their electronically recorded drug intake data, as well as a multicompartment pillbox. Patients will be then randomised to one of two groups in a crossover design, so that in the subsequent 6-month interventional phase one group will use a (reminder-delivering) "Reminder Card" for the first 3 months and the "Smart Card" for the last 3 months, while the second group will use the cards in reverse order.

NCT ID: NCT03334968 Completed - Stroke, Ischemic Clinical Trials

Prolidase Enzyme Activity in Stroke Patients

Start date: May 1, 2016
Phase: N/A
Study type: Observational

Stroke is a major cerebrovascular disease that causes significant burdens for human health and life, including high morbidity, mortality, and disability. Prolidase enzyme activity was found in various organs, such as the heart, brain, thymus, kidney, lung, pancreas, and spleen, and in plasma, leukocytes, erythrocytes, and dermal fibroblasts. An increase in collagen turnover is known to be correlated with increased prolidase enzyme activity. The aim of this study was to investigate whether SPA levels in AIS patients can be used as a potential diagnostic and prognostic marker. SPA levels were prospectively evaluated in 37 patients aged between 20 and 85 years who were admitted within 24 hours of the onset of AIS. The control group included 37 healthy volunteers of similar age without any disease.

NCT ID: NCT03320018 Active, not recruiting - Stroke, Ischemic Clinical Trials

Neuroprotection in Acute Ischemic Stroke

Start date: August 2, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This is a pilot randomized control trial (RCT) to explore the possible beneficial effect of a novel combination therapy consisting of molecular hydrogen H2 plus minocycline ("H2M"), on neurological recovery after acute ischemic stroke.

NCT ID: NCT03291392 Recruiting - Genetic Disease Clinical Trials

CUHK Stroke Biobank

Start date: June 15, 2015
Phase: N/A
Study type: Observational

The purpose of the study are: 1. To make quality, characterized samples and related data available for future studies, including Genome Wide Association Studies (GWAS), genomics, and biomarker research; 2. To use these samples and related medical information to answer research questions aimed at understanding the genetics and underlying biology of acquired disease and injury to the brain, heart and blood vessels with the express purpose of advancing the search for effective modalities for prevention, treatment, and recovery; 3. To develop additional operational infrastructure to support this project across the Prince of Wales Hospital and divisions, including (1) tracking of patient consent, (2) management of collection and sample processing processes, (3) sample inventory and QC/QA processes, and (4) release of materials to investigators for further research.

NCT ID: NCT03275155 Recruiting - Atrial Fibrillation Clinical Trials

Pathophysiology and Risk of Atrial Fibrillation Detected After Ischemic Stroke

Start date: April 18, 2017
Phase: N/A
Study type: Observational

This prospective non-interventional cohort study investigates the pathophysiology of Atrial Fibrillation Detected After Stroke or transient ischemic attack (AFDAS) by comparing the autonomic function and inflammation between patients with AFDAS, patients with atrial fibrillation (AF) diagnosed before the ischemic event or known AF (KAF), and patients with normal sinus rhythm (NSR) after 14 day of cardiac monitoring following the event onset.

NCT ID: NCT03243318 Not yet recruiting - Stroke, Ischemic Clinical Trials

Motor Evoked Potential in the Affected Upper Limb Predicts the Potential of Motor Recovery After Ischemic Stroke

Start date: October 1, 2017
Phase: N/A
Study type: Observational

Stroke is the third common cause of adult disability in dveloped countries. Early identification of the potential for motor recovery is important to avoid 'learned disuse' and to initiate appropriate therapy with achievable goals. The current cohort study focuses on those patients with SAFE <8 and using motor evoked potentials (MEPs) to improve on prognostication of upper limb motor recovery among subacute stroke patients in a local stroke population.

NCT ID: NCT03211130 Not yet recruiting - Stroke, Ischemic Clinical Trials

Using SystemCHANGE™ to Enhance Medication Adherence in Older Adult Stroke Survivors

Start date: October 2017
Phase: Early Phase 1
Study type: Interventional

This study evaluated the feasibility and acceptability of using a SystemCHANGE intervention in older adult stroke survivors to improve medication adherence. Half the participants will receive the SystemCHANGE intervention, while the other half will receive the attention-control education intervention.